RxDoctor Payments Data

Walter Beebe, MD

Ophthalmology · Dallas, TXNPI 1093742207

Payments from drug & device makers

$5,631in general payments, 2019–2025

Across 82 payments — averaging $68.68 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Kala Pharmaceuticals, Inc.$3K
  • Bausch & Lomb, A Division Of Bausch Health US, LLC$1K
  • Alcon$604
  • Sun Pharmaceutical Industries Inc.$278
  • Biotissue Holdings Inc.$175
  • AbbVie$124
  • plus $441 from 11 others

What the payments were for

  • Speaking & faculty fees$3,75067%
  • Food & beverage$1,86233%
  • Gifts$190%

General payments by program year

19
20
21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$5,631 in reported general payments places this provider in the 75th percentile of 1,355 ophthalmology providers in Texas.

See all ophthalmology providers in Texas

Medicare billing

Part B allowed, 2024
$67,337
Medicare patients
314
Services billed
500

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
RestasisCyclosporine39$52,171
Prednisolone Acetate258$15,778
XiidraLifitegrast15$14,062
Fluorometholone84$6,321
Cyclosporine13$5,056
Loteprednol Etabonate36$4,114
ValacyclovirValacyclovir Hcl59$3,682
Difluprednate20$1,943
MoxifloxacinMoxifloxacin Hcl44$939
Acyclovir39$718
Ofloxacin19$253
ErythromycinErythromycin Base19$239
Dorzolamide-TimololDorzolamide Hcl/Timolol Maleat13$228
Latanoprost13$87
Timolol Maleate11$70

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
AbbVieRestasis$124$52,17139 claims
Bausch & Lomb Americas Inc.Xiidra$72$14,06215 claims
Bausch & Lomb, A Division Of Bausch Health US, LLCLoteprednol Etabonate$1,321$4,11436 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 75th percentile of 1,355 ophthalmology providers in Texas.

Other ophthalmology in Dallas

See the full list for Texas

Where these figures come from

Is this you, or does something look wrong? →